Back to top
more

Verona Pharma (VRNA)

(Delayed Data from NSDQ)

$15.47 USD

15.47
260,511

+0.16 (1.05%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $15.47 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VRNA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Verona Pharma PLC American Depositary Share [VRNA]

Reports for Purchase

Showing records 141 - 160 ( 189 total )

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 141

11/05/2019

Company Report

Pages: 9

Q3 Financials Uneventful; Top-line Ensifentrine/COPD Phase 2b Data Around YE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 142

10/18/2019

Industry Report

Pages: 10

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 143

10/17/2019

Company Report

Pages: 9

Ensifentrine/COPD: Ph2b Fully Enrolled; Data Release by YE; Ph3 Starts in 2020

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 144

10/15/2019

Company Report

Pages: 9

Expanded Analysis of Phase 2b Data at CHEST

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 145

09/27/2019

Daily Note

Pages: 10

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 146

09/20/2019

Industry Report

Pages: 10

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 147

09/19/2019

Company Report

Pages: 9

Ensifentrine/DPI: Positive Interim Ph2 Data at ERS Supports Future Partnership

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 148

08/06/2019

Company Report

Pages: 10

Q2; Cash Runway into Q2:20; Attractive Valuation in Front of Catalysts

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 149

08/05/2019

Company Report

Pages: 10

Positive DPI Phase 2 Results Expands Ensifentrine COPD Commercial Opportunity

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 150

08/02/2019

Daily Note

Pages: 10

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 151

07/29/2019

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 152

07/29/2019

Daily Note

Pages: 9

Ensifentrine/COPD: Key Catalysts in H2; Ph3 to Start in 2020

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 153

06/04/2019

Daily Note

Pages: 8

Ensifentrine MDI Phase 2 Trial Initiated; Interim Data in H2

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 154

05/24/2019

Industry Report

Pages: 13

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 155

05/20/2019

Company Report

Pages: 7

Verona Presents Expanded Analysis of Ensifentrine/COPD at ATS

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 156

05/13/2019

Company Report

Pages: 11

Q1; R-D Day Takeaways; Key Data Readouts Anticipated in 2019

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 157

05/13/2019

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 158

05/06/2019

Daily Note

Pages: 10

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 159

03/05/2019

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Verona Pharma PLC American Depositary Share

Industry: Medical - Biomedical and Genetics

Record: 160

03/04/2019

Daily Note

Pages: 8

Positive Interim Esifentrine DPI Phase 2 Data Reported

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party